Science Explorer Back to mapMap
Discussion
Company · Waltham · United States

ImmunoGen (United States)

In research, ImmunoGen (United States) stands highest in Health Sciences (#8,593 of 16,688 worldwide) and Medicine (#10,254 of 14,558 worldwide), over all time.

immunogen.comROR OpenAlex
World rank, all time
#28,412
of 34,923
Rank in United States
#5,961
of 7,310
Research works
305
▼ 73% vs 2018-21
Citations
18k
57.8 per fractional work
Top-10% rate
22.3%
all institutions 10.0%
vs its own fields
1.09×
1.00× is exactly expected
Open access
24%
world 40%
International
12%
world 18%
ImmunoGen (United States)

What is ImmunoGen (United States) known for in research?

The fields where it stands highest, over all time, ranked among every institution above the floor in each field.

FieldWorld rankWhere that sitsTop-10% rateWorks
Health SciencesDomain #8,593 of 16,688 28.8%189
MedicineField #10,254 of 14,558 28.7%188

Each strip is that field's whole ranked pool, with the notch where ImmunoGen (United States) sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no average mark, because the average differs by field (from about 6% in Dentistry to 21% in Economics).

Which fields of science does ImmunoGen (United States) work in?

In all years, 62% of research at ImmunoGen (United States) is in Health Sciences, 28% in Life Sciences. Its largest fields are Medicine (62%), Biochemistry, Genetics and Molecular Biology (21%), Chemistry (7%). It does 2.6× the world's share of Health Sciences.

Health Sciences: 189 fractional works · 62.0% of its workMedicine: 188 fractional works · 61.8% of its workOncology: 78 fractional works · 25.8% of its workRadiology, Nuclear Medicine and Imaging: 64 fractional works · 21.1% of its workHematology: 8 fractional works · 2.5% of its workPulmonary and Respiratory Medicine: 6 fractional works · 2.1% of its workEpidemiology: 5 fractional works · 1.6% of its workPathology and Forensic Medicine: 4 fractional works · 1.5% of its workReproductive Medicine: 4 fractional works · 1.4% of its workGenetics: 3 fractional works · 1.0% of its workImmunology and Allergy: 3 fractional works · 0.9% of its workPublic Health, Environmental and Occupational Health: 2 fractional works · 0.5% of its workRheumatology: 1 fractional works · 0.5% of its workEndocrinology, Diabetes and Metabolism: 1 fractional works · 0.5% of its workNeurology: 1 fractional works · 0.5% of its workInfectious Diseases: 1 fractional works · 0.4% of its workSurgery: 1 fractional works · 0.3% of its workDermatology: 1 fractional works · 0.2% of its workSmaller subfields together: 3 fractional works · 1.0% of its workNursing: 1 fractional works · 0.2% of its workNutrition and Dietetics: 1 fractional works · 0.2% of its workHealth Professions: 0 fractional works · 0.0% of its workLife Sciences: 86 fractional works · 28.4% of its workBiochemistry, Genetics and Molecular Biology: 65 fractional works · 21.4% of its workMolecular Biology: 44 fractional works · 14.4% of its workBiotechnology: 7 fractional works · 2.2% of its workCell Biology: 3 fractional works · 1.1% of its workGenetics: 3 fractional works · 1.1% of its workCancer Research: 3 fractional works · 1.0% of its workBiochemistry: 2 fractional works · 0.8% of its workPhysiology: 1 fractional works · 0.5% of its workBiophysics: 1 fractional works · 0.2% of its workImmunology and Microbiology: 19 fractional works · 6.3% of its workImmunology: 17 fractional works · 5.4% of its workParasitology: 2 fractional works · 0.5% of its workSmaller subfields together: 1 fractional works · 0.3% of its workAgricultural and Biological Sciences: 1 fractional works · 0.3% of its workPharmacology, Toxicology and Pharmaceutics: 1 fractional works · 0.2% of its workNeuroscience: 0 fractional works · 0.2% of its workPhysical Sciences: 29 fractional works · 9.6% of its workChemistry: 22 fractional works · 7.1% of its workOrganic Chemistry: 19 fractional works · 6.3% of its workSpectroscopy: 2 fractional works · 0.8% of its workEngineering: 5 fractional works · 1.6% of its workBiomedical Engineering: 4 fractional works · 1.4% of its workSmaller subfields together: 0 fractional works · 0.2% of its workMaterials Science: 1 fractional works · 0.5% of its workBiomaterials: 1 fractional works · 0.2% of its workSmaller subfields together: 1 fractional works · 0.3% of its workEnvironmental Science: 1 fractional works · 0.2% of its workMathematics: 0 fractional works · 0.1% of its workEarth and Planetary Sciences: 0 fractional works · 0.1% of its workComputer Science: 0 fractional works · 0.0% of its workALL ITS WORKImmunoGen (UnitedStates)305fractional works, all years
Life Sciences28%Physical Sciences10%Health Sciences62%Social Sciences0%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 17 fields, with their numbers
    1. Medicine18861.8%
    2. Nursing10.2%
    3. Health Professions00.0%
    1. Biochemistry, Genetics and Molecular Biology6521.4%
    2. Immunology and Microbiology196.3%
    3. Agricultural and Biological Sciences10.3%
    4. Pharmacology, Toxicology and Pharmaceutics10.2%
    5. Neuroscience00.2%
    1. Chemistry227.1%
    2. Engineering51.6%
    3. Materials Science10.5%
    4. Environmental Science10.2%
    5. Mathematics00.1%
    6. Earth and Planetary Sciences00.1%
    7. Computer Science00.0%
    8. Chemical Engineering00.0%
    1. Decision Sciences00.0%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Who are the top researchers at ImmunoGen (United States)?

Ranked on the quality score, Thomas A. Keating, Victor S. Goldmacher and Wayne C. Widdison lead among researchers whose main affiliation is ImmunoGen (United States).

  1. 1 Thomas A. Keating United States · #227,312 worldwide 5.5k citations · 116 works
  2. 2 Victor S. Goldmacher United States · #316,131 worldwide 8.6k citations · 156 works
  3. 3 Wayne C. Widdison United States · #366,646 worldwide 3.8k citations · 70 works
  4. 4 Peter U. Park United States · #369,529 worldwide 2.5k citations · 92 works
  5. 5 Yelena Kovtun United States · #388,993 worldwide 5.8k citations · 94 works
  6. 6 Kathleen R. Whiteman United States · #395,300 worldwide 3.5k citations · 75 works
  7. 7 Thomas D. Chittenden United States · #453,943 worldwide 5.9k citations · 69 works
  8. 8 Leanne Lanieri United States · #470,189 worldwide 1.1k citations · 74 works
  9. 9 John M. Lambert United States · #479,040 worldwide 11k citations · 188 works
  10. 10 Robert J. Lutz United States · #500,510 worldwide 11k citations · 191 works
All ranked researchers at ImmunoGen (United States)

What are the most cited papers from ImmunoGen (United States)?

The most cited paper from ImmunoGen (United States) is "p53 Has a Direct Apoptogenic Role at the Mitochondria" (Motohiro Mihara, Susan H. Erster, Alexander I. Zaika et al., 2003), with 1,779 citations. Next come "Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate" (1,695) and "Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy" (927).

Most cited papers
#PaperReleasedCitations
1 p53 Has a Direct Apoptogenic Role at the Mitochondria Motohiro Mihara, Susan H. Erster, Alexander I. Zaika et al. · Molecular Cell Open access Mar 2003 1,779
2 Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate Gail D. Lewis Phillips, Guangmin Li, Debra L. Dugger et al. · Cancer Research 14 Nov 2008 1,695
3 Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy Ravi V. J. Chari, Michael Laurence Miller, Wayne C. Widdison · Angewandte Chemie International Edition 20 Feb 2014 927
4 Puma is an essential mediator of p53-dependent and -independent apoptotic pathways John R. Jeffers, Evan Parganas, Youngsoo Lee et al. · Cancer Cell Open access Oct 2003 884
5 Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs Ravi V. J. Chari · Accounts of Chemical Research 18 Aug 2007 816
All 61 most cited papers, with filters and sorting

Which keywords describe research at ImmunoGen (United States)?

By fractional works in all years, weighted toward what it does more of than the world: Chemotherapy, Glycosylation, Breast Cancer, Monoclonal Antibodies, Therapeutic Antibodies, Monoclonal Antibody, Antibody Engineering and Fc Receptors.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Chemotherapy64▲ 30×12 topics
  2. Glycosylation60▲ 89×3 topics
  3. Breast Cancer57▲ 67×4 topics
  4. Monoclonal Antibodies57▲ 130×3 topics
  5. Therapeutic Antibodies56▲ 142×2 topics
  6. Monoclonal Antibody53▲ 250×2 topics
  7. Antibody Engineering53▲ 173×1 topic
  8. Fc Receptors53▲ 173×1 topic
  9. HER252▲ 560×1 topic
  10. Metastatic52▲ 269×2 topics
  11. Trastuzumab52▲ 397×1 topic
  12. Targeted Therapy23▲ 35×5 topics
  13. Cancer Therapy21▲ 11×12 topics
  14. PET Imaging19▲ 29×4 topics
  15. Cancer16▲ 3.8×20 topics
  16. Immunotherapy14▲ 6.9×11 topics
  17. Lymphoma13▲ 30×3 topics
  18. Synthesis12▲ 7.0×8 topics
  19. Biological Evaluation12▲ 31×4 topics
  20. Cancer Treatment11▲ 14×2 topics
  21. Radioimmunotherapy11▲ 93×1 topic
  22. Radiopharmaceuticals11▲ 93×1 topic
  23. Tumor Regression11▲ 42×2 topics
  24. Cancer Immunotherapy11▲ 25×2 topics
  25. Metastatic Breast Cancer10▲ 49×2 topics
  26. Immunotoxin10▲ 100×1 topic
  27. Ricin Poisoning10▲ 100×1 topic
  28. Leukemia10▲ 48×2 topics
  29. CAR T Cells10▲ 72×1 topic
  30. Chimeric Antigen Receptor10▲ 72×1 topic
  31. Biopharmaceuticals9▲ 44×3 topics
  32. Prognostic Factors9▲ 6.5×9 topics
  33. Angiogenesis9▲ 7.1×7 topics
  34. Recombinant Proteins8▲ 52×2 topics
  35. Tumor Microenvironment8▲ 7.6×6 topics
  36. Medicinal Chemistry7▲ 6.4×7 topics
  37. Anticancer Agents7▲ 8.9×5 topics
  38. Rituximab7▲ 14×2 topics
  39. Cell Cycle Control7▲ 86×2 topics
  40. Anticancer Drugs6▲ 49×2 topics

Which research topics does ImmunoGen (United States) publish most on?

By volume in 2022-now: HER2/EGFR in Cancer Research, Ovarian cancer diagnosis and treatment, Advanced Breast Cancer Therapies and Monoclonal and Polyclonal Antibodies Research.

HER2/EGFR in Cancer Rese…2HER2/EGFR in Cancer Research: 2 fractional worksOvarian cancer diagnosis…2Ovarian cancer diagnosis and treatment: 2 fractional worksAdvanced Breast Cancer Therapies: 1 fractional worksMonoclonal and Polyclonal Antibodies Research: 1 fractional worksCAR-T cell therapy research: 1 fractional worksFolate and B Vitamins Re…1Folate and B Vitamins Research: 1 fractional worksAcute Lymphoblastic Leukemia research: 1 fractional worksVirus-based gene therapy research: 0 fractional worksImmunotherapy and Immune Responses: 0 fractional worksCancer Immunotherapy and Biomarkers: 0 fractional works
OncologyReproductive MedicinePulmonary and Respiratory MedicineRadiology, Nuclear Medicine and Imaging4 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 HER2/EGFR in Cancer Research Oncology 2 works
  2. 2 Ovarian cancer diagnosis and treatment Reproductive Medicine 2 works
  3. 3 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 1 works
  4. 4 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 1 works
  5. 5 CAR-T cell therapy research Oncology 1 works
  6. 6 Folate and B Vitamins Research Rheumatology 1 works
  7. 7 Acute Lymphoblastic Leukemia research Public Health, Environmental and Occupational Health 1 works
  8. 8 Virus-based gene therapy research Genetics 0 works
  9. 9 Immunotherapy and Immune Responses Immunology 0 works
  10. 10 Cancer Immunotherapy and Biomarkers Oncology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available23.8%not open76.2%

World: 40% of research is openly available.

with international co-authors12.4%domestic only87.6%

World: 18% is written across borders.

How has ImmunoGen (United States)'s research output changed?

Output in 2022-2025 was 73% lower than in 2018-2021.

still counting1990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is ImmunoGen (United States) as a percentage of every work published that year, 0.000078% in 2024.

still counting0.00050%0.0010%0.0015%ImmunoGen (United States)0.000056% in 20251990200020102020

Fractional works of ImmunoGen (United States) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Waltham

All research institutions in Waltham

Share ImmunoGen (United States)'s ranking

ImmunoGen (United States) on Science Explorer

A card with ImmunoGen (United States)'s standing and the fields it leads in, for a post or a slide. A link to this page previews as the same card.

Download the card

1200 × 630 PNG, sized for social posts, drawn from the latest snapshot.

Badges for a website1Each links back here and updates with every snapshot

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about ImmunoGen (United States). Posts are plain text and can be reported.